
RevealDx: Seattle AI Profile — Product, Footprint & Verified Record

Verified: November 19, 2026 · Canonical URL: https://tygartmedia.com/revealdx-seattle-wa-ai-profile/

Verified Record Summary: As of November 19, 2026, RevealDx operates as an independent, privately held Seattle clinical AI company headquartered on Westlake Avenue North with approximately 9 employees tracked by PitchBook. Following U.S. FDA 510(k) clearance in February 2026 and an August 2026 US$3.4M Series A led by strategic partner 4DMedical (which holds a 10% stake and distribution rights), RevealDx is scaling commercial deployment of RevealAI-Lung across U.S., European, and Australian radiology markets. Cumulative venture funding ranges from ~$7.85M in PitchBook tracking to $12M+ across longer corporate history reported by GeekWire.



Field	Verified Record (As of Nov 19, 2026)
Company	RevealDx
Official Website	https://www.reveal-dx.com/
Washington HQ	Seattle, WA (1800 Westlake Ave. N, Suite 104, Seattle, WA 98109)
Other WA Footprint	2026 GeekWire Awards Innovation Finalist; backed by Pacific Northwest angel networks Alliance of Angels and Frontier Angels
Founded	2021 (reorganized from Mindshare Medical, founded 2014)
Founders / Leadership	Chris Wood (CEO), Michael Calhoun (CTO), Dr. Ryan Brevard (Director of Clinical Programs), David Austin (VP of Sales)
Stage	Series A
Announced Funding	~$7.85M–$12M+ (includes Aug 2026 US$3.4M / A$4.9M Series A led by 4DMedical)
Team Size	~9 (PitchBook)
Primary Ecosystem Ties	Seattle Westlake HQ, Alliance of Angels & Frontier Angels (investors), 2026 GeekWire Awards Innovation Finalist

What RevealDx Builds

RevealDx develops RevealAI-Lung, a U.S. FDA 510(k)-cleared (K251769) computer-aided diagnostic (CADx) AI software application designed to analyze radiomic digital biomarkers on chest CT scans. Its clinical purpose, detailed on the RevealDx official website, is to assist radiologists in distinguishing benign pulmonary nodules from lung cancer earlier in the evaluation workflow.

The software computes a continuous Malignancy Similarity Index (mSI™) score from 0 to 1—grouped into low, intermediate, and high risk bands. In the United States, RevealAI-Lung and its mSI™ score are cleared for evaluating incidentally-detected pulmonary nodules measuring 6–15 mm in diameter in patients aged 18 and older, and are explicitly not indicated for routine lung cancer screening in the U.S.

Washington Footprint and Leadership

RevealDx is headquartered along Lake Union at 1800 Westlake Ave. N, Suite 104, Seattle, WA 98109, with roughly 9 employees recorded by PitchBook. Its corporate history reflects two distinct milestones: CTO Michael Calhoun founded predecessor company Mindshare Medical in 2014 to develop the underlying lung-nodule radiomics technology, before the business was acquired and reorganized under Precision Medical Ventures in 2021 to operate as RevealDx under CEO Chris Wood, as outlined on the RevealDx Company page and in GeekWire's 2024 coverage.

As regulatory clearances converted into active commercial rollout in late 2026, the company expanded its clinical and go-to-market bench. On November 2, 2026, RevealDx announced via its November 2026 leadership press release the appointments of Dr. Ryan Brevard (previously a Medical Advisor) as Director of Clinical Programs and medtech executive David Austin as Vice President of Sales.

Products, Users, and Public Traction

RevealDx builds for radiologists, hospital lung nodule programs, health systems, and clinical imaging providers managing incidental CT findings. Rather than selling solely through a small direct sales team, the company has assembled clinical workflow integrations and distribution partnerships tracked in the RevealDx Press Room. Key partners include Azra AI (a May 2026 partnership integrating RevealAI-Lung nodule characterization into Azra's oncology workflow and incidental findings platform), technical integrations with Riverain Technologies and Fuji PACS, U.S. distributor Sirona, and global distributor 4DMedical.

In clinical validation cited on the RevealDx official website, the company's clearance reader study on size-matched nodules smaller than 8 mm reported that ten radiologists improved diagnostic accuracy from an unaided AUC of 0.459 to 0.728 with mSI™ assistance, while retrospective validation across more than 1,500 diagnosed cases indicated mSI™ would have accelerated follow-up in 45% (range 33–59%) of guideline-deferred cancers. RevealDx is also exhibiting at RSNA 2026 (November 29–December 2, 2026, South Hall AI Showcase Booth 5930).

Funding, Stage, and Place in Washington's AI Landscape

In August 2026, Melbourne-based respiratory imaging company 4DMedical led RevealDx's Series A with a US$3.4M (A$4.9M) strategic investment. As disclosed in the 4DMedical partnership announcement, the financing gave 4DMedical a 10% fully diluted equity stake, one board seat, and a right of first negotiation over any future sale, while leaving RevealDx an independent, privately held Seattle corporation.

Across data providers, total disclosed venture funding for RevealDx spans a range from approximately $7.85M in PitchBook records to $12M+ when incorporating cumulative historical funding reported by GeekWire across its earlier rounds (including a $4.2M raise covered by GeekWire in 2024). Backed by A-Level Capital, Alliance of Angels, Frontier Angels, Frost Data Capital, Life Science Angels, and 4DMedical, RevealDx stands out in Washington's health AI cohort for pairing regulated FDA 510(k) and EU MDR clearances with established CPT reimbursement codes on a lean capital base.

Verified Primary Sources & Official References

- RevealDx Official Website: https://www.reveal-dx.com/
- RevealDx Company Page: https://www.reveal-dx.com/company/
- RevealDx Press Room: https://www.reveal-dx.com/press/
- 4DMedical Distribution Agreement Press Release: https://www.reveal-dx.com/press/4dmedical-distribution-agreement/
- November 2026 Leadership Expansion Press Release: https://www.reveal-dx.com/press/revealdx-expands-leadership-Nov-2026/
- GeekWire — RevealDx $4.2M Funding Coverage: https://www.geekwire.com/2024/seattle-startup-revealdx-lands-4-2m-to-help-clinicians-diagnose-lung-cancer/

Companion Markdown twin: https://tygartmedia.com/wp-content/uploads/2026/11/revealdx-seattle-wa-ai-profile.md (also mirrored at https://tygartmedia.com/revealdx-seattle-wa-ai-profile.md). Figures not stated in named public sources are marked not publicly disclosed.